Cargando…

Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is characterised by numerous abnormalities in B lineage cells, including increased CD27++ plasmablasts/plasma cells, atypical CD27-IgD- B cells with increased CD95, spleen tyrosine kinase (Syk)++, CXCR5- and CXCR5+ subsets and anergic CD11c+Tbet+ age-associated B c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dörner, Thomas, Szelinski, Franziska, Lino, Andreia C, Lipsky, Peter E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425190/
https://www.ncbi.nlm.nih.gov/pubmed/32675278
http://dx.doi.org/10.1136/rmdopen-2020-001258
_version_ 1783570450201182208
author Dörner, Thomas
Szelinski, Franziska
Lino, Andreia C
Lipsky, Peter E
author_facet Dörner, Thomas
Szelinski, Franziska
Lino, Andreia C
Lipsky, Peter E
author_sort Dörner, Thomas
collection PubMed
description Systemic lupus erythematosus (SLE) is characterised by numerous abnormalities in B lineage cells, including increased CD27++ plasmablasts/plasma cells, atypical CD27-IgD- B cells with increased CD95, spleen tyrosine kinase (Syk)++, CXCR5- and CXCR5+ subsets and anergic CD11c+Tbet+ age-associated B cells. Most findings, together with preclinical lupus models, support the concept of B cell hyperactivity in SLE. However, it remains largely unknown whether these specific B cell subsets have pathogenic consequences and whether they provide relevant therapeutic targets. Recent findings indicate a global distortion of B cell functional capability, in which the entire repertoire of naïve and memory B cells in SLE exhibits an anergic or postactivated (APA) functional phenotype. The APA status of SLE B cells has some similarities to the functional derangement of lupus T cells. APA B cells are characterised by reduced global cytokine production, diminished B cell receptor (BCR) signalling with decreased Syk and Bruton’s tyrosine kinase phosphorylation related to repeated in vivo BCR stimulation as well as hyporesponsiveness to toll-like receptor 9 engagement, but intact CD40 signalling. This APA status was related to constitutive co-localisation of CD22 linked to phosphatase SHP-1 and increased overall protein phosphatase activities. Notably, CD40 co-stimulation could revert this APA status and restore BCR signalling, downregulate protein tyrosine phosphatase transcription and promote B cell proliferation and differentiation. The APA status and their potential rescue by bystander help conveyed through CD40 stimulation not only provides insights into possible mechanisms of escape of autoreactive clones from negative selection but also into novel ways to target B cells therapeutically.
format Online
Article
Text
id pubmed-7425190
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-74251902020-08-24 Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus Dörner, Thomas Szelinski, Franziska Lino, Andreia C Lipsky, Peter E RMD Open Lupus Systemic lupus erythematosus (SLE) is characterised by numerous abnormalities in B lineage cells, including increased CD27++ plasmablasts/plasma cells, atypical CD27-IgD- B cells with increased CD95, spleen tyrosine kinase (Syk)++, CXCR5- and CXCR5+ subsets and anergic CD11c+Tbet+ age-associated B cells. Most findings, together with preclinical lupus models, support the concept of B cell hyperactivity in SLE. However, it remains largely unknown whether these specific B cell subsets have pathogenic consequences and whether they provide relevant therapeutic targets. Recent findings indicate a global distortion of B cell functional capability, in which the entire repertoire of naïve and memory B cells in SLE exhibits an anergic or postactivated (APA) functional phenotype. The APA status of SLE B cells has some similarities to the functional derangement of lupus T cells. APA B cells are characterised by reduced global cytokine production, diminished B cell receptor (BCR) signalling with decreased Syk and Bruton’s tyrosine kinase phosphorylation related to repeated in vivo BCR stimulation as well as hyporesponsiveness to toll-like receptor 9 engagement, but intact CD40 signalling. This APA status was related to constitutive co-localisation of CD22 linked to phosphatase SHP-1 and increased overall protein phosphatase activities. Notably, CD40 co-stimulation could revert this APA status and restore BCR signalling, downregulate protein tyrosine phosphatase transcription and promote B cell proliferation and differentiation. The APA status and their potential rescue by bystander help conveyed through CD40 stimulation not only provides insights into possible mechanisms of escape of autoreactive clones from negative selection but also into novel ways to target B cells therapeutically. BMJ Publishing Group 2020-07-15 /pmc/articles/PMC7425190/ /pubmed/32675278 http://dx.doi.org/10.1136/rmdopen-2020-001258 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Lupus
Dörner, Thomas
Szelinski, Franziska
Lino, Andreia C
Lipsky, Peter E
Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title_full Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title_fullStr Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title_full_unstemmed Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title_short Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus
title_sort therapeutic implications of the anergic/postactivated status of b cells in systemic lupus erythematosus
topic Lupus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425190/
https://www.ncbi.nlm.nih.gov/pubmed/32675278
http://dx.doi.org/10.1136/rmdopen-2020-001258
work_keys_str_mv AT dornerthomas therapeuticimplicationsoftheanergicpostactivatedstatusofbcellsinsystemiclupuserythematosus
AT szelinskifranziska therapeuticimplicationsoftheanergicpostactivatedstatusofbcellsinsystemiclupuserythematosus
AT linoandreiac therapeuticimplicationsoftheanergicpostactivatedstatusofbcellsinsystemiclupuserythematosus
AT lipskypetere therapeuticimplicationsoftheanergicpostactivatedstatusofbcellsinsystemiclupuserythematosus